Matches in SemOpenAlex for { <https://semopenalex.org/work/W2336697896> ?p ?o ?g. }
Showing items 1 to 74 of
74
with 100 items per page.
- W2336697896 endingPage "14" @default.
- W2336697896 startingPage "105" @default.
- W2336697896 abstract "To evaluate the safety and tolerability of long-term treatment with olanzapine versus risperidone in schizophrenic outpatients with prominent negative symptoms.This was a multi-center, randomised, open-label, parallel, dose-flexible, 1 year study of outpatients with schizophrenia (DSM-IV criteria) with prominent negative symptoms (SANS Global score > or =10). Safety was evaluated by recording treatment-emergent adverse events, vital signs, body weight and, when available, laboratory parameters. Extrapyramidal symptoms (EPS) were evaluated by a questionnaire based on the UKU scale, and sexual dysfunction by the Psychotropic-Related Sexual Dysfunction Questionnaire (PRSexDQ).The mean (+/- SD) modal dose throughout the study was 12.3 (+/- 6.3) mg/day for olanzapine and 5.2 (+/- 2.5) mg/day for risperidone. EPS were significantly more frequent in the risperidone-treated patients 50.4 % versus 28.9 % for olanzapine (p = 0.0006). Olanzapine patients showed significantly greater reductions (improvement) from baseline in the PRSexDQ score (p=0.0292) and risperidone patients reported significantly more sexual adverse events (21.1% versus 7.3% for olanzapine; p=0.0018). Mean body weight gain was not significantly different at endpoint (3.5 kg gained with olanzapine versus 1.9 kg gained with risperidone; p=0.3522), but the proportion of patients showing a body weight increase > or =7% was higher among the olanzapine-treated patients (37.8% versus 16.8%; p=0.0012).Significantly less treatment-emergent extrapyramidal and sexual adverse events were observed in patients treated with olanzapine compared to those treated with risperidone. Mean body weight increases with both drugs were not significantly different after one year. Olanzapine patients presented a significantly higher incidence of clinically important body weight increase when compared with patients treated with risperidone." @default.
- W2336697896 created "2016-06-24" @default.
- W2336697896 creator A5013983043 @default.
- W2336697896 creator A5014740458 @default.
- W2336697896 creator A5024756328 @default.
- W2336697896 creator A5046434743 @default.
- W2336697896 creator A5087904407 @default.
- W2336697896 date "2007-04-03" @default.
- W2336697896 modified "2023-09-26" @default.
- W2336697896 title "[Safety and tolerability of olanzapine versus risperidone: a one-year randomized study in outpatients with schizophrenia with prominent negative symptoms]." @default.
- W2336697896 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17401781" @default.
- W2336697896 hasPublicationYear "2007" @default.
- W2336697896 type Work @default.
- W2336697896 sameAs 2336697896 @default.
- W2336697896 citedByCount "5" @default.
- W2336697896 countsByYear W23366978962018 @default.
- W2336697896 countsByYear W23366978962023 @default.
- W2336697896 crossrefType "journal-article" @default.
- W2336697896 hasAuthorship W2336697896A5013983043 @default.
- W2336697896 hasAuthorship W2336697896A5014740458 @default.
- W2336697896 hasAuthorship W2336697896A5024756328 @default.
- W2336697896 hasAuthorship W2336697896A5046434743 @default.
- W2336697896 hasAuthorship W2336697896A5087904407 @default.
- W2336697896 hasConcept C118552586 @default.
- W2336697896 hasConcept C126322002 @default.
- W2336697896 hasConcept C15744967 @default.
- W2336697896 hasConcept C197934379 @default.
- W2336697896 hasConcept C2776412080 @default.
- W2336697896 hasConcept C2776619155 @default.
- W2336697896 hasConcept C2778375690 @default.
- W2336697896 hasConcept C2780057945 @default.
- W2336697896 hasConcept C2780494398 @default.
- W2336697896 hasConcept C2780616385 @default.
- W2336697896 hasConcept C2780948584 @default.
- W2336697896 hasConcept C2781353949 @default.
- W2336697896 hasConcept C42219234 @default.
- W2336697896 hasConcept C513476851 @default.
- W2336697896 hasConcept C71924100 @default.
- W2336697896 hasConceptScore W2336697896C118552586 @default.
- W2336697896 hasConceptScore W2336697896C126322002 @default.
- W2336697896 hasConceptScore W2336697896C15744967 @default.
- W2336697896 hasConceptScore W2336697896C197934379 @default.
- W2336697896 hasConceptScore W2336697896C2776412080 @default.
- W2336697896 hasConceptScore W2336697896C2776619155 @default.
- W2336697896 hasConceptScore W2336697896C2778375690 @default.
- W2336697896 hasConceptScore W2336697896C2780057945 @default.
- W2336697896 hasConceptScore W2336697896C2780494398 @default.
- W2336697896 hasConceptScore W2336697896C2780616385 @default.
- W2336697896 hasConceptScore W2336697896C2780948584 @default.
- W2336697896 hasConceptScore W2336697896C2781353949 @default.
- W2336697896 hasConceptScore W2336697896C42219234 @default.
- W2336697896 hasConceptScore W2336697896C513476851 @default.
- W2336697896 hasConceptScore W2336697896C71924100 @default.
- W2336697896 hasIssue "2" @default.
- W2336697896 hasLocation W23366978961 @default.
- W2336697896 hasOpenAccess W2336697896 @default.
- W2336697896 hasPrimaryLocation W23366978961 @default.
- W2336697896 hasRelatedWork W1702790997 @default.
- W2336697896 hasRelatedWork W1864525495 @default.
- W2336697896 hasRelatedWork W1973807164 @default.
- W2336697896 hasRelatedWork W1988965841 @default.
- W2336697896 hasRelatedWork W2067511747 @default.
- W2336697896 hasRelatedWork W2081994983 @default.
- W2336697896 hasRelatedWork W2104813914 @default.
- W2336697896 hasRelatedWork W2119813684 @default.
- W2336697896 hasRelatedWork W2336697896 @default.
- W2336697896 hasRelatedWork W2413580062 @default.
- W2336697896 hasVolume "35" @default.
- W2336697896 isParatext "false" @default.
- W2336697896 isRetracted "false" @default.
- W2336697896 magId "2336697896" @default.
- W2336697896 workType "article" @default.